文献速递眼整形与眼眶角膜与眼表疾病

肉毒毒素对眼轮匝肌痉挛患者眼表参数影响的系统评价与Meta分析

Impact of Botulinum Toxin on Ocular Surface Parameters in Patients With Orbicularis Spasm: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Ophthalmol · 2026-09-16

结果显示OSDI在1至4周和3个月显著改善,TBUT在3个月显著增加,Schirmer试验和荧光素染色保持稳定,散光小幅降低。作者指出这些效应可能继发于眼睑不自主收缩减少,不应解读为BTX对眼表的直接生物学作用。

要点

  • BTX治疗后OSDI在1至4周和3个月均显著改善。
  • TBUT在3个月显著增加,Schirmer试验和荧光素染色保持稳定。
  • BTX与散光小幅降低相关,但效应可能继发于痉挛减少。

核心结论

  • BTX可改善眼轮匝肌痉挛患者的眼表症状和泪膜稳定性,对Schirmer试验中性,并降低散光。
  • 这些效应可能受眼睑不自主收缩减少影响,不应解读为BTX对眼表生理的直接生物学作用证据。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase和Cochrane至2025年6月。
  • 纳入标准为入组≥7例眼轮匝肌痉挛患者并报告治疗前后结局的研究。

主要发现

  • OSDI在1至4周显著改善(MD -11.77;95%CI -19.93至-0.28;P < .001),3个月亦显著改善(MD -7.43;P < .0001)。
  • TBUT在3个月显著增加(MD 0.81;95%CI 0.20-1.43;P < .01)。
  • Schirmer试验I和荧光素染色在所有时间区间保持稳定(P > .05)。
  • Meta回归显示注射位点更多与1个月时Schirmer试验I更高相关(R² = 80.3%;P < .001)。
  • BTX与散光小幅但显著降低相关(MD -0.14;P < .01)。

关键数值与推荐

  • 主要终点包括Schirmer试验I、泪膜破裂时间、眼表疾病指数、荧光素染色和散光。
  • OSDI在1至4周MD -11.77(95%CI -19.93至-0.28;P < .001),3个月MD -7.43(P < .0001)。
  • TBUT在3个月MD 0.81(95%CI 0.20-1.43;P < .01)。
  • 散光MD -0.14(P < .01)。

临床怎么用

  • 临床解读BTX治疗后眼表参数变化时,应考虑眼睑痉挛减少的间接效应而非BTX直接作用。
  • OSDI和TBUT可作为监测BTX治疗眼轮匝肌痉挛患者眼表症状和泪膜稳定性的指标。
  • Schirmer试验和荧光素染色在BTX治疗后预期保持稳定,无需常规因这些指标变化调整治疗。

局限性

  • 效应可能受眼睑不自主收缩减少影响,无法区分BTX直接生物学作用。
  • 未来需结合客观眼表和痉挛评估的研究以阐明潜在机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: Although botulinum toxin (BTX) is the primary treatment for facial dystonias and spasms, its effects on the ocular surface and corneal metrics are poorly defined and contradictory in the current literature. CLINICAL RELEVANCE: This systematic review and meta-analysis provides standardized evidence to support the interpretation of BTX-related ocular surface outcomes in patients with blepharospasm and hemifacial spasm. METHODS: We searched PubMed, Embase, and Cochrane up to June 2025 using terms related to orbicularis spasm and ocular surface parameters. Eligible articles enrolled ≥7 patients with orbicularis spasm and reported pre- and posttreatment outcomes. Primary end points included Schirmer Test I (ST1), tear break-up time (TBUT), ocular surface disease index (OSDI), fluorescein staining, and astigmatism. A single-arm random-effects model in R was used to estimate mean differences (MDs). RESULTS: Twenty-six studies (820 patients, 1147 eyes) were included. OSDI scores significantly improved at 1 to 4 weeks (MD, -11.77; 95% CI, -19.93 to -0.28; P < .001) and 3 months (MD, -7.43; P < .0001). TBUT showed a significant increase at 3 months (MD, 0.81; 95% CI, 0.20-1.43; P < .01). ST1 and fluorescein staining remained stable across all intervals (P > .05), though meta-regression revealed that more injection sites correlated with higher ST1 at 1 month (R² = 80.3%; P < .001). Additionally, BTX was associated with a small but significant reduction in astigmatism (MD, -0.14; P < .01). CONCLUSION: BTX improves ocular surface symptoms and tear film stability in orbicularis oculi spasm, with neutral effects on Schirmer tests and reduced astigmatism. However, since these effects are likely influenced by the reduction of involuntary eyelid contractions, these findings should not be interpreted as evidence of a direct biologic effect of BTX on ocular surface physiology. Future studies incorporating objective ocular surface and spasm assessments are needed to clarify the underlying mechanisms.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Veiga DM, Fujimura Júnior AY, Goldfarb Cyrino L, et al. Impact of Botulinum Toxin on Ocular Surface Parameters in Patients With Orbicularis Spasm: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2026. PMID: 42749245. doi:10.1016/j.ajo.2026.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。